Clinical Context Randomized controlled trials establish efficacy under ideal conditions, but real-world effectiveness may differ due to patient selection, adherence patterns, and clinical heterogeneity. The SUSTAIN and PIONEER programs demonstrated semaglutide’s impressive glycemic and weight effects in carefully selected populations following strict protocols. Whether these benefits translate to routine clinical practice—where patients are less homogeneous, adherence is variable, and comparators reflect actual prescribing patterns—remained an important question. Pragmatic trials bridge this gap by randomizing patients in real-world settings with minimal exclusion criteria and comparing treatments as they’re actually used. This design sacrifices some internal validity for enhanced external validity and…
Author: FWA
Clinical Context Type 2 diabetes is paradoxically associated with increased fracture risk despite often-normal or even elevated bone mineral density (BMD). This “diabetes bone paradox” reflects impaired bone quality—changes in microarchitecture, collagen cross-linking, and accumulated advanced glycation end-products (AGEs) that weaken bone independent of BMD. Postmenopausal women with diabetes face compounded risk from both estrogen deficiency and diabetes-related bone fragility. The choice of diabetes medication may influence bone health. Thiazolidinediones (pioglitazone, rosiglitazone) increase fracture risk, particularly in women, through PPAR-gamma activation that shifts bone marrow stromal cells toward adipocyte rather than osteoblast differentiation. SGLT2 inhibitors have raised concerns about potential…
Summary: In patients with comorbid hypertension and diabetes, an interdisciplinary collaborative care model combined with family empowerment based on the COM-B model significantly improved blood pressure and glucose control, as well as psychosocial adaptation compared to routine care, though it was associated with no major reported side effects. PICO Description Population Patients diagnosed with comorbid hypertension and diabetes mellitus. Intervention Interdisciplinary collaborative care model (ICCM) combined with family empowerment (FE), utilizing the COM-B behavioral framework to enhance clinical management and psychosocial support. Comparison Routine clinical care without structured family empowerment or COM-B model-based interventions. Outcome Significant improvements observed in blood…
Summary: In patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes mellitus, combined treatment with metformin and ezetimibe significantly improved PPAR-gamma and adiponectin gene expression and biochemical parameters compared to metformin monotherapy, though it was associated with mild, manageable side effects without severe adverse events. PICO Description Population Adult patients diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) concomitant with type 2 diabetes mellitus. Intervention Combined therapy of metformin plus ezetimibe administered for six months (Met + EZY group). Comparison Metformin monotherapy for six months (Met group). Outcome Combined metformin and ezetimibe significantly enhanced expression of PPAR-gamma…
Clinical Context Diabetic foot ulcers (DFUs) affect approximately 15-25% of people with diabetes during their lifetime and are the leading cause of non-traumatic lower limb amputation. Despite advances in wound care, many DFUs remain recalcitrant, with healing rates of only 30-50% at 12 weeks with standard treatment. The impaired healing environment in diabetes—characterized by chronic inflammation, impaired angiogenesis, cellular senescence, and deficient growth factor signaling—creates a hostile wound bed that resists conventional therapies. Mesenchymal stem cells (MSCs) have emerged as promising wound healing agents due to their ability to modulate inflammation, promote angiogenesis, and stimulate tissue regeneration. However, direct cell…
Summary: In obese patients with type 2 diabetes mellitus, orlistat combined with pioglitazone and metformin significantly improved glycemic control and reduced body weight compared to pioglitazone and metformin alone, though it was associated with increased gastrointestinal side effects. PICO Description Population Obese patients diagnosed with type 2 diabetes mellitus enrolled from multiple centers in Shanghai, China. Intervention Orlistat combined with pioglitazone and metformin administered according to standard dosing regimens over the study period. Comparison Treatment with pioglitazone and metformin without orlistat in obese patients with type 2 diabetes mellitus. Outcome Combination therapy significantly improved glycemic indices and promoted weight loss…
Clinical Context Perioperative hyperglycemia and glucose variability are independent predictors of poor outcomes after cardiac surgery, including increased mortality, sternal wound infection, atrial fibrillation, and prolonged ICU stay. Diabetic patients undergoing coronary artery bypass grafting (CABG) are at particularly high risk: surgical stress triggers counter-regulatory hormone release (cortisol, catecholamines, glucagon) that induces insulin resistance and hyperglycemia even in non-diabetics. In patients with pre-existing diabetes, this stress response amplifies already impaired glucose homeostasis. Managing perioperative glucose is challenging. Insulin infusion protocols attempt to maintain tight control but risk hypoglycemia—itself associated with adverse outcomes. Glucose variability (fluctuations in glucose levels) may be…
Summary: In patients with diabetic foot ulcers, including those with peripheral artery disease, intramuscular human placenta-derived cells (PDA-002) at doses of 3 × 10⁶, 10 × 10⁶, and 30 × 10⁶ cells significantly improved ulcer healing rates compared to placebo, though it was associated with mild to moderate adverse events including injection site reactions. PICO Description Population Adults with diabetic foot ulcers, stratified by presence or absence of peripheral artery disease, enrolled in a Phase 2 multicenter trial. Intervention Intramuscular administration of human placenta-derived cells (PDA-002) at three dosing regimens: 3 × 10⁶, 10 × 10⁶, and 30 × 10⁶…
Clinical Context Pediatric type 1 diabetes management remains challenging despite advances in technology. While continuous glucose monitoring (CGM) provides unprecedented visibility into glucose patterns, the data alone doesn’t improve outcomes—it’s what patients and families do with the data that matters. Many children and adolescents with type 1 diabetes remain above target, with mean HbA1c levels in pediatric diabetes registries typically ranging from 8.0-9.0%, well above the recommended target of less than 7.0%. The traditional model of quarterly clinic visits leaves families to navigate daily diabetes management largely on their own between appointments. This interval is too long to address the…
Summary: In adults with persistent and recalcitrant diabetic foot ulcers that failed to heal with conventional treatment, full-thickness decellularized placental membrane allograft (FT-DPM) applied to the debrided wound bed for 5-9 days with reapplication as needed demonstrated significantly increased complete wound closure rates and accelerated healing time compared to standard of care alone including wound debridement and moist wound therapy without allograft, with primary adverse events limited to mild to moderate wound site irritation that did not prevent continued treatment. PICO Description Population Adults with persistent and recalcitrant diabetic foot ulcers that failed to heal with conventional treatment. Intervention Full-thickness…